Incorporated in Bordeaux in 2018, TreeFrog Therapeutics is a French-based biotech startup aimed at making cell therapies safer, more efficient, more accessible and more affordable for millions of patients.
The C-Stem™ technology introduces:
TreeFrog is advancing a pipeline of cell therapies targeting high-burden and currently incurable chronic and degenerative diseases, including blood and immune disorders, Parkinson’s disease, as well as heart and liver failure.
TreeFrog Therapeutics was co-founded by Kevin Alessandri, PhD, an expert in 3D-printed microfluidics, and Maxime Feyeux, a stem cell biologist who was one of first PhD students worldwide to work on pluripotent stem cells.
Awarded with top innovation grants at French & European level (i-LAB, i-Nov, EIC accelerator), TreeFrog also attracted over $82M in private investments over the past 3 years.
Bringing together physicists, cell biologists and bioproduction engineers
self-dubbed the froggies, the TreeFrog team will grow 3-fold over the next 3 years, expanding in France, USA and Japan.
Focused on bringing the benefits of C-Stem™ as fast as possible to patients, TreeFrog is partnering with market leaders in EU, USA and Japan to develop cell therapies with mass-market potential.